Document:

EX-10.22

 Exhibit 10.22 

Execution Version 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (“Agreement”) is entered into as of October 28, 2020, by and among (i) LianBio, an
exempted company organized under the laws of the Cayman Islands (the “Company”), (ii) Konstantin Poukalov (the “Director”), and (iii) Perceptive Life Sciences Master Fund, Ltd., Perceptive Xontogeny Venture
Fund, LP, and LEV LB Holdings, LP (collectively, the “Fund”, and together with each of the Fund’s limited partners and general partners, the “Fund Indemnitees”). The Director and the Fund Indemnitees shall be
referred to herein individually as the “Indemnitee” and collectively as the “Indemnitees”. 
 RECITALS

 A. The Company and the Indemnitees recognize the continued difficulty in obtaining liability insurance for its directors, officers, employees, agents
and fiduciaries, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance. 
 B. The Company and
the Indemnitees further recognize the substantial increase in corporate litigation in general, subjecting directors, officers, employees, controlling persons, shareholders, agents and fiduciaries to expensive litigation risks at the same time as the
availability and coverage of liability insurance has been severely limited. 
 C. The Company desires to attract and retain the services of highly qualified
individuals, such as the Director and wishes to provide for indemnification to each Indemnitee. 
 In view of the considerations set forth
above, the Company desires that each Indemnitee be indemnified by the Company as set forth herein. 
 NOW, THEREFORE, the Company and each
Indemnitee hereby agree as follows: 
  

	1.	 Indemnification. 

(a) Indemnification of Expenses. 

(i) Third-Party Claims. The Company shall indemnify and hold harmless the Director to the fullest extent permitted by applicable law if
the Director was or is or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness, any threatened, pending action, suit, proceeding or alternative dispute resolution mechanism, or any hearing, inquiry
or investigation that might lead to the institution of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, investigative or other (a “Claim”) (other than an action
by right of the Company) by reason of (or arising in part out of) any event or occurrence related to the fact that the Director is or was a director of the Company, or any subsidiary of the Company, or is or was serving at the request of the Company
as a director of another corporation, partnership, limited liability company, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of the Director while serving in such capacity (an “Agent”)
or as a direct or indirect result of any Claim made by any shareholder of the Company against the Director and arising out of or related to any round of financing of the Company (including but not limited to Claims regarding
non-

 
participation, or non-pro rata participation, in such round by such shareholder), or made by a third party against the Director based on any misstatement
or omission of a material fact by the Company in violation of any duty of disclosure imposed on the Company by securities or common laws (an “Indemnification Event”) against any and all expenses (if and to the extent reasonable),
judgments, fines, penalties and amounts paid in settlement (if, and only if, such settlement is approved in advance by the Company) of such Claim and any federal, state, local or foreign taxes imposed on an Indemnitee as a result of the actual
receipt of any payments under this Agreement (collectively, the “Expenses”), including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses. Such payment of the Expenses shall
be made by the Company as soon as practicable but in any event no later than twenty (20) days after written demand by an Indemnitee therefore is presented to the Company. 

(ii) Derivative Actions. If the Director was or is a party or is threatened to be made a party to any Claim by or on behalf of the
Company to procure a judgment in its favor by reason of the fact that he is or was an Agent of the Company, or by reason of anything done or not done by him in any such capacity, the Company shall indemnify the Director against any amounts paid in
settlement (if, and only if, such settlement is approved in advance by the Company) of any such Claim and all Expenses actually and reasonably incurred by him in connection with the investigation, defense, settlement or appeal of such Claim if he
acted in good faith and in a manner he reasonably believed to be in, or not opposed to, the best interests of the Company. 
 (iii)
Indemnification of Fund Indemnitees. The Company agrees that, if and whenever a Fund Indemnitee is or was a party or is threatened to be made a party to or is in any way involved in any Claim (including without limitation any such Claim
brought by or in the right of the Company), by reason of the fact that (i) the Director is or was an Agent, (ii) by reason of anything done or not done by the Director in such capacity, or (iii) by reason of the fact that a Fund
Indemnitee is or was acting as an express agent of the Company upon the request of the Company and solely for the benefit of the Company (provided that the fact that a Fund Indemnitee will incidentally benefit as a shareholder from such
action will not alone mean that such action is not or was not solely for the benefit of the Company), the Company shall indemnify each Fund Indemnitee against all Expenses actually and reasonably incurred by such Fund Indemnitee or on such Fund
Indemnitee’s behalf in connection with such Claim, except to the extent that any such Expenses arise from a Claim for which the Director is not entitled to indemnification hereunder pursuant to Section 8(a) hereof or
under applicable law. 
 (b) Reviewing Party. Notwithstanding the foregoing, (i) the obligations of the Company under
Section 1(a) shall be subject to the condition that the Reviewing Party (as described in Section 10(e) hereof) shall not have determined in writing (or in a written opinion, in case the Independent
Legal Counsel referred to in Section 1(f) hereof is involved) that an Indemnitee would not be permitted to be indemnified under applicable law, and (ii) the obligation of the Company to make an advance payment of
Expenses to an Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall be subject to the condition that, if, when and to the extent that the Reviewing Party determines that such Indemnitee would
not be permitted to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by the Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid; provided, however, that if the
Indemnitee has commenced or thereafter commences legal 

  
 -2- 

 
proceedings in a court of competent jurisdiction to secure a determination that such Indemnitee should be indemnified under applicable law, any determination made by the Reviewing Party that the
Indemnitee would not be permitted to be indemnified under applicable law shall not be binding and the Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial determination is made with respect thereto
(as to which all rights of appeal therefrom have been exhausted or lapsed). The Indemnitee’s obligation to reimburse the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon. If there has not been a Change
in Control (as defined in Section 10(c) hereof), the Reviewing Party shall be selected by the Company’s board of directors (“Board” or “Board of Directors”), and if there has been such
a Change in Control (other than a Change in Control which has been approved by a majority of the Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party shall be the Independent Legal Counsel referred
to in Section 1(f) hereof. If there has been no determination by the Reviewing Party or if the Reviewing Party determines that the Indemnitee substantively would not be permitted to be indemnified in whole or in part under
applicable law, such Indemnitee shall have the right to commence litigation seeking an initial determination by the court or challenging any such determination by the Reviewing Party or any aspect thereof, including the legal or factual bases
therefor, and the Company hereby consents to service of process and to appear in any such proceeding. Any determination by the Reviewing Party otherwise shall be conclusive and binding on the Company and the Indemnitees. 

(c) Contribution. If the indemnification provided for in Section 1(a) above for any reason other than the
statutory limitations of applicable law, is held by a court of competent jurisdiction to be unavailable to an Indemnitee in respect of any losses, claims, damages, expenses or liabilities in which the Company is jointly liable with such Indemnitee,
as the case may be (or would be jointly liable if joined), then the Company, in lieu of indemnifying the Indemnitee thereunder, shall contribute to the amount actually and reasonably incurred and paid or payable by the Indemnitee as a result of such
losses, claims, damages, expenses or liabilities in such proportion as is appropriate to reflect (i) the relative benefits received by the Company and the Indemnitee, and (ii) the relative fault of the Company and such Indemnitee in
connection with the action or inaction that resulted in such losses, claims, damages, expenses or liabilities, as well as any other relevant equitable considerations. The relative fault of the Company and the Indemnitee shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or the Indemnitee and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent the circumstances resulting in such losses, claims, damages, expenses or liabilities. 

(d) The Company and the Indemnitees agree that it would not be just and equitable if contribution pursuant to this
Section 1(c) were determined solely by pro rata or per capita allocation or by any other method of allocation which does not take into account the equitable considerations referred to in the immediately preceding paragraph.
No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the United States Securities Act of 1933, as amended) shall be entitled to contribution from any person who was not found guilty of such fraudulent
misrepresentation. 

  
 -3- 

 (e) Survival Regardless of Investigation. The indemnification and contribution
provided for in this Section 1 will remain in full force and effect regardless of any investigation made by or on behalf of the Indemnitees. 

(f) Change in Control. The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Board of Directors who were directors immediately prior to such Change in Control) then, with respect to all matters thereafter arising concerning the rights of Indemnitees to payments of the Expenses and Expense
Advances under this Agreement or any other agreements or under the Company’s Memorandum and Articles of Association, as amended and restated, Independent Legal Counsel (as defined in Section 10(d) hereof) shall be
selected by the Indemnitees and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee
would be permitted to be indemnified under applicable law and the Company agrees to abide by such opinion. The Company agrees to pay the reasonable fees of the Independent Legal Counsel referred to above and to fully indemnify such counsel against
any and all expenses (including attorneys’ fees, if and to the extent reasonable), claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

(g) Mandatory Payment of Expenses. Notwithstanding any other provision of this Agreement other than Section 9
hereof, to the extent an Indemnitee has been successful on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in defense of any Claim referred to in Section 1(a) hereof or
in the defense of any claim, issue or matter therein, such Indemnitee shall be indemnified against all Expenses incurred by the Indemnitee in connection therewith. 
  

	2.	 Expenses; Indemnification Procedure. 

(a) Advancement of Expenses. The Company shall advance all Expenses incurred by an Indemnitee. The advances to be made hereunder shall
be paid by the Company to the Indemnitee as soon as practicable but in any event no later than twenty (20) days after written demand by the Indemnitee therefor to the Company, which demand will include a statement or statements from the
Indemnitee requesting such advance or advances from time to time and must include written evidence from third parties independent of and not connected with the Indemnitee to support the amount of such Expenses to be incurred. 

(b) Notice/Cooperation by Indemnitee. An Indemnitee shall, as a condition precedent to Indemnitee’s right to be indemnified under
this Agreement, (i) give the Company notice in writing as soon as practicable after receipt of notice of commencement of any Claim made against such Indemnitee for which indemnification will or could be sought under this Agreement; and
(ii) give the Company written evidence from third parties independent of and not connected with the Indemnitee to support the amount of the Expenses incurred. Notice to the Company shall be directed to the Chief Executive Officer of the Company
at the address shown on the signature page of this Agreement (or such other address as the Company shall designate in writing to the Indemnitee). In addition, Indemnitee shall give the Company such information and cooperation as it may reasonably
require and as shall be within Indemnitee’s power. 

  
 -4- 

 (c) No Presumptions; Burden of Proof. For purposes of this Agreement, the termination
of any Claim by judgment, order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent, shall not create a presumption that an Indemnitee did not meet any particular standard of
conduct or have any particular belief or that a court has determined that indemnification is not permitted by applicable law. In addition, neither the failure of the Reviewing Party to have made a determination as to whether the Indemnitee has met
any particular standard of conduct or had any particular belief, nor an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct or did not have such belief, prior to the commencement of legal proceedings by
the Indemnitee to secure a judicial determination that the Indemnitee should be indemnified under applicable law, shall be a defense to the Indemnitee’s claim or create a presumption that the Indemnitee has not met any particular standard of
conduct or did not have any particular belief. In connection with any determination by the Reviewing Party or otherwise as to whether the Indemnitee is entitled to be indemnified hereunder, the burden of proof shall be on the Company to establish
that the Indemnitee is not so entitled. 
 (d) Notice to Insurers. If, at the time of the receipt by the Company of a notice of a
Claim pursuant to Section 2(b) hereof, the Company has director and officer liability insurance in effect which may cover such Claim, the Company shall give prompt notice of the commencement of such Claim to the insurers in
accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of an Indemnitee, all amounts payable as a result of such action, suit,
proceeding, inquiry or investigation in accordance with the terms of such policies. 
 (e) Selection of Counsel. In the event the
Company shall be obligated hereunder to pay the Expenses of any Claim, an Indemnitee shall be entitled to request that the Company assume the defense of such Claim with legal counsel reasonably approved by the Indemnitee, upon the delivery to the
Company of written notice of its election to do so. After delivery of such notice, approval of such counsel by the Indemnitee, and the retention of such counsel by the Company, the Company will not be liable to such Indemnitee under this Agreement
for any fees of counsel subsequently incurred by such Indemnitee with respect to the same Claim; provided that, (i) the Indemnitee shall have the right to employ separate legal counsel in any such Claim at the Indemnitee’s expense and
(ii) if (A) the employment of separate legal counsel by the Indemnitee has been previously authorized by the Company, (B) such Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and such
Indemnitee in the conduct of any such defense, or (C) the Company shall not continue to retain the legal counsel originally appointed to defend such Claim, then the reasonable fees and expenses of the Indemnitee’s separate legal counsel
shall be at the expense of the Company. The Company shall conduct the defense of the Indemnitee in good faith and in consultation with the Indemnitee and legal counsel, and the Company shall not settle any claim against the Indemnitee without the
express written consent of the Indemnitee. 

  
 -5- 

	3.	 Additional Indemnification Rights; Non-exclusivity.

 (a) Scope. The Company hereby agrees to indemnify the Indemnitees to the fullest extent permitted by law,
notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement or any other agreements, the Company’s Memorandum and Articles of Association, as amended and restated, or by statute. In the
event of any change after the date of this Agreement in any applicable law, statute or rule which expands the right of a Cayman Islands company to indemnify a member of its board of directors or an officer, employee, controlling person, shareholder,
agent or fiduciary, it is the intent of the parties hereto that the Indemnitees shall enjoy by this Agreement the greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule which narrows the right of
a Cayman Islands company to indemnify a member of its board of directors or an officer, employee, controlling person, shareholder, agent or fiduciary, such change, to the extent not otherwise required by such law, statute or rule to be applied to
this Agreement, shall have no effect on this Agreement or the parties’ rights and obligations hereunder except as set forth in Section 8(a) hereof. 

(b) Non-exclusivity. Notwithstanding anything in this Agreement, the indemnification provided by
this Agreement shall be in addition to any rights to which Indemnitees may be entitled under the Company’s Memorandum and Articles of Association, as amended and restated, any agreement, any vote of shareholders or disinterested directors, the
laws of the Cayman Islands, or otherwise. Notwithstanding anything in this Agreement, the indemnification provided under this Agreement shall continue as to each Indemnitee for any action Indemnitee took or did not take while serving in an
indemnified capacity even though the Indemnitee may have ceased to serve in such capacity. 
  

	4.	 No Duplication of Payments. 

The Company shall not be liable under this Agreement to make any payment in connection with any Claim made against any Indemnitee to the extent
such Indemnitee has otherwise actually received payment (under any insurance policy, or the Company’s Memorandum and Articles of Association, as amended and restated, or otherwise) of the amounts otherwise indemnifiable hereunder. 

 

	5.	 Partial Indemnification. 

If any Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses
incurred in connection with any Claim, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses to which such Indemnitee is entitled. 

 

	6.	 Mutual Acknowledgment. 

Both the Company and each Indemnitee acknowledge that in certain instances, applicable law or public policy may prohibit the Company from
indemnifying its directors, officers, employees, controlling persons, shareholders, agents or fiduciaries under this Agreement or otherwise. Each Indemnitee understands and acknowledges that if the Company is subject to the informational
requirements of the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company may be required to undertake with the Securities and Exchange Commission to submit the question of indemnification to a
court in certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee. 

  
 -6- 

	7.	 Liability Insurance. 

The Company shall, from time to time, make good faith determinations as to whether or not it is practicable for the Company to obtain and
maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company, to the fullest extent permitted by applicable law, with coverage for losses from Claims, or to ensure the
Company’s performance of its indemnification obligations under this Agreement. Among other considerations, the Company will weigh the costs of obtaining such insurance coverage against the protection afforded by such coverage. In all policies
of directors’ and officers’ liability insurance, an Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s
directors. 
  

	8.	 Exceptions. 

Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement: 

(a) Excluded Action or Omissions. To indemnify an Indemnitee for Expenses resulting from acts, omissions or transactions for which
Indemnitee is prohibited from receiving indemnification under this Agreement or applicable law; 
 (b) Claims Initiated by Indemnitee.
To indemnify or advance expenses to an Indemnitee with respect to Claims initiated or brought voluntarily by the Indemnitee and not by way of defense, except (i) with respect to actions or proceedings brought to establish or enforce a right to
indemnification under this Agreement or any other agreement or insurance policy or under the Company’s Memorandum of Association or Articles of Association now or hereafter in effect relating to Claims for Indemnification Events, or
(ii) in specific cases if the Board has approved the initiation or bringing of such Claim; 
 (c) Lack of Good Faith. To
indemnify an Indemnitee for any reasonable expenses incurred by the Indemnitee with respect to any proceeding instituted by the Indemnitee to enforce or interpret a right to indemnification under this Agreement, if a court of competent jurisdiction
determines that each of the material assertions made by the Indemnitee in such proceeding was not made in good faith or was frivolous; or 

(d) Claims Under Section 16(b). To indemnify an Indemnitee for expenses and the payment of profits arising from the
purchase and sale by such Indemnitee of securities in violation of the provisions of Section 16(b) of the Exchange Act or any similar successor statute if the Company is subject to the informational requirements of the
Exchange Act. 
  

	9.	 Period of Limitations. 

No legal action shall be brought and no cause of action shall be asserted by or on behalf of the Company against the Indemnitee, the
Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be
extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5)-year period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such shorter
period shall govern. 

  
 -7- 

	10.	 Construction of Certain Phrases. 

(a) For purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, employees,
controlling person, shareholders, agents or fiduciaries, so that if any Indemnitee is or was or may be deemed a director, officer, employee, controlling person, shareholder, agent or fiduciary of such constituent corporation, or is or was or may be
deemed to be serving at the request of such constituent corporation as a director, officer, employee, controlling person, shareholder, trustee, general partner, managing member, agent or fiduciary of another corporation, partnership, joint venture,
employee benefit plan, trust or other enterprise, each Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such
constituent corporation if its separate existence had continued. 
 (b) For purposes of this Agreement, references to “other
enterprises” shall include employee benefit plans; references to “fines” shall include any excise taxes assessed on the Director with respect to an employee benefit plan; and references to “serving at the request of the
Company” shall include any service as a director, officer, employee, controlling person, shareholder, agent or fiduciary of the Company which imposes duties on, or involves services by, such director, officer, employee, controlling person,
shareholder, agent or fiduciary with respect to an employee benefit plan, its participants or its beneficiaries; and if the Director acted in good faith and in a manner the Director reasonably believed to be in the interest of the participants and
beneficiaries of an employee benefit plan, the Director shall be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement. 

(c) For purposes of this Agreement a “Change in Control” shall be deemed to have occurred if, on or after the date of this
Agreement, (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company acting in such capacity or a
corporation owned directly or indirectly by the shareholders of the Company in substantially the same proportions as their ownership of stock of the Company, becomes the “beneficial owner” (as defined in Rule 13(d)(3) under the Exchange
Act), directly or indirectly, of securities of the Company representing more than thirty percent (30%) of the total voting power represented by the Company’s then outstanding Voting Securities, (ii) during any period of two
(2) consecutive years, individuals who at the beginning of such period constitute the Board and any new director whose election by the Board or nomination for election by the Company’s shareholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to
constitute a majority thereof, or (iii) the shareholders of the Company approve a merger or consolidation of the Company with any other corporation other than a merger or consolidation which would result in the Voting Securities of

  
 -8- 

 
the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least two-thirds (2/3rds) of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the shareholders of the
Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of related transactions) all or substantially all of the Company’s assets. 

(d) For purposes of this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in
accordance with the provisions of Section 1(f) hereof, who shall not have otherwise performed services for the Company or any Indemnitee within the last two (2) years (other than with respect to matters concerning the
right of any Indemnitee under this Agreement, or of other indemnitees under similar indemnity agreements). 
 (e) For purposes of this
Agreement, a “Reviewing Party” shall mean any appropriate person or body consisting of a member or members of the Board or any other person or body appointed by the Board who is not a party to the particular Claim for which
Indemnitee is seeking indemnification, or Independent Legal Counsel. 
 (f) For purposes of this Agreement, “Voting
Securities” shall mean any securities of the Company that vote generally in the election of directors. 
  

	11.	 Counterparts. 

This Agreement may be executed in one or more counterparts, each of which shall constitute an original. 

 

	12.	 Binding Effect; Successors and Assigns. 

This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors,
assigns, including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business and/or assets of the Company, spouses, heirs, and personal and legal representatives. The Company shall
require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance
satisfactory to each Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. This Agreement shall continue in
effect with respect to Claims relating to Indemnification Events regardless of whether any Indemnitee continues to serve as a director, officer, employee, controlling person, shareholder, agent or fiduciary of the Company or of any other enterprise,
including subsidiaries of the Company, at the Company’s request. 

  
 -9- 

	13.	 Attorneys’ Fees. 

In the event that any action is instituted by an Indemnitee under this Agreement or under any liability insurance policies maintained by the
Company to enforce or interpret any of the terms hereof or thereof, such Indemnitee shall be entitled to be paid all Expenses incurred by such Indemnitee with respect to such action, regardless of whether any Indemnitee is ultimately successful in
such action, and shall be entitled to the advancement of Expenses with respect to such action, unless, as a part of such action, a court of competent jurisdiction over such action determines that each of the material assertions made by Indemnitee as
a basis for such action was not made in good faith or was frivolous. In the event of an action instituted by or in the name of the Company under this Agreement to enforce or interpret any of the terms of this Agreement, the Indemnitee shall be
entitled to be paid all Expenses incurred by such Indemnitee in defense of such action (including costs and expenses incurred with respect to the Indemnitee’s counterclaims and cross-claims made in such action), and shall be entitled to the
advancement of Expenses with respect to such action, unless, as a part of such action, a court of competent jurisdiction over such action determines that each of Indemnitee’s material defenses to such action was made in bad faith or was
frivolous. 
  

	14.	 Notice. 

All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given:
(a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) two (2) business days after deposit with an internationally recognized overnight courier, specifying next business day delivery,
with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page, or to such e-mail address, facsimile number or address as
subsequently modified by written notice given in accordance with this Section 14. 
  

	15.	 Dispute Resolution. 

(a) Any dispute, controversy or claim (each, a “Dispute”) arising out of or relating to this Agreement, or the interpretation,
breach, termination, validity or invalidity thereof, shall be referred to and conclusively determined by arbitration upon the demand of any party to the dispute with notice (the “Arbitration Notice”) to the other party or parties.

 (b) The Dispute shall be settled by arbitration in Hong Kong Special Administrative Region of the People’s Republic of China
(“Hong Kong”) by the Hong Kong International Arbitration Centre (the “HKIAC”) in accordance with the Hong Kong International Arbitration Centre Administered Arbitration Rules (the “HKIAC Rules”) in
force when the Arbitration Notice is submitted in accordance with the HKIAC Rules. 
 (c) The disputing parties may jointly select one
(1) arbitrator, or agree that the Chairman of HKIAC shall select the arbitrator. In the absence of such agreement, there shall be three (3) arbitrators, the claimant to the Dispute, or in the case of multiple claimants, all such claimants
acting collectively (the “Claimant”) shall select one (1) arbitrator and the respondent to the Dispute, or in the case of more than one respondent, the respondents acting collectively (the “Respondent”) shall
select one (1) arbitrator. All selections shall be made within thirty (30) days after the selecting party gives or receives the demand for arbitration. Such arbitrators shall be freely selected, and neither the Claimant nor the Respondent
shall be limited in their selection to any prescribed list. The Chairman of HKIAC shall select the third arbitrator who will act as chairman of the arbitration board. If any arbitrator to be appointed by a party has not been appointed and consented
to participate within thirty (30) days after the selection of the first arbitrator, the relevant appointment shall be made by the Chairman of HKIAC. 

  
 -10- 

 (d) The arbitral proceedings shall be conducted in English. To the extent that the HKIAC
Rules are in conflict with the provisions of this Section, including the provisions concerning the appointment of the arbitrators, the provisions of this Section shall prevail. 

(e) Each party to the arbitration shall cooperate with each other party to the arbitration in making full disclosure of and providing complete
access to all information and documents requested by such other party in connection with such arbitral proceedings, subject only to any confidentiality obligations binding on such party. 

(f) The award of the arbitral tribunal shall be final and binding upon the parties thereto, and the prevailing party may apply to a court of
competent jurisdiction for enforcement of such award. 
 (g) The arbitral tribunal shall decide any Dispute submitted by the parties to the
arbitration strictly in accordance with the substantive laws of Hong Kong (without regard to principles of conflict of laws thereunder) and shall not apply any other substantive law. 

(h) Any party to the Dispute shall be entitled to seek preliminary injunctive relief, if possible, from any court of competent jurisdiction
pending the constitution of the arbitral tribunal. 
 (i) During the course of the arbitral tribunal’s adjudication of the Dispute, this
Agreement shall continue to be performed except with respect to the part in dispute and under adjudication. 
 (j) Notwithstanding the
foregoing in this Section 15, the parties agree that each party shall have the right, without posting any bond, to seek preliminary injunction, temporary restraining order or other temporary relief from any court of
competent jurisdiction. 
  

	16.	 Severability. 

The provisions of this Agreement shall be severable in the event that any of the provisions hereof (including any provision within a single
section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid, void or otherwise unenforceable, and the remaining provisions shall remain enforceable to the fullest extent permitted by law. Furthermore, to the fullest
extent possible, the provisions of this Agreement (including, without limitations, each portion of this Agreement containing any provision held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or unenforceable) shall
be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. 

  
 -11- 

	17.	 Choice of Law. 

This Agreement shall be governed by and construed under the laws of Hong Kong, without giving effect to any choice of law rule that would cause
the application of the laws of any other jurisdiction. 
  

	18.	 Primacy of Indemnification. 

Notwithstanding that the Indemnitee may have certain rights to indemnification, advancement of expenses and/or insurance provided by other
persons (collectively, the “Other Indemnitors”), the Company (i) shall be the indemnitor of first resort (i.e., its obligations to the Indemnitee are primary and any obligation of the Other Indemnitors to advance expenses or to
provide indemnification for the same expenses or liabilities incurred by the Indemnitee are secondary); (ii) shall required to advance the full amount of expenses incurred by the Indemnitee and shall be liable for the full amount of all Expenses,
without regard to any rights the Indemnitee may have against any of the Other Indemnitors; and (iii) irrevocably waives, relinquishes and releases the Other Indemnitors for any and all claims against the Other Indemnitors for contribution,
subrogation or any other recovery of any kind in respect thereof. No advancement or payment by the Other Indemnitors on behalf of the Indemnitee with respect to any claim for which the Indemnitee has sought indemnification from the Company shall
affect the immediately preceding sentence, and the Other Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of the Indemnitee against the Company. The
Company and the Indemnitee agree that the Other Indemnitors are express third party beneficiaries of the terms of this Section 18. 
  

	19.	 Subrogation. 

In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of
the Indemnitees who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights. 

 

	20.	 Amendment and Termination. 

No amendment, modification, termination or cancellation to/of this Agreement shall be effective unless it is in writing signed by all the
parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 

 

	21.	 Integration and Entire Agreement. 

Subject to Section 3, this Agreement sets forth the entire understanding between the parties hereto and supersedes
and merges all previous written and oral negotiations, commitments, understandings and agreements relating to the subject matter hereof between the parties hereto. 

  
 -12- 

	22.	 No Construction as Employment Agreement. 

Nothing contained in this Agreement shall be construed as giving the Indemnitees any right to be retained in the employ of the Company or any
of its subsidiaries. 
 [The remainder of this page has been left intentionally blank] 

  
 -13- 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. 
  

							
	LIANBIO	  		  	Address: LianBio
		  		  		  	c/o Ogier Global (Cayman) Limited
		  		  	                	  	89 Nexus Way, Camana Bay
		  		  		  	Grand Cayman, KY1-9009, Cayman Islands
				
	By:	  	 /s/ Bing Li
	  		  	
	Name:	  	Bing Li	  		  	Attn: Bing Li
	Title:	  	Authorized Representative	  		  	

 [Signature Page to Indemnification Agreement] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. 
  

							
	AGREED TO AND ACCEPTED BY:	 	                	  	
	Director	 		  	Address: 95 Horatio St, apt PhD
		 		 		  	NY 10014, New York, United States
	By:	 	 /s/ Konstantin Poukalov
	 		  	
	Name:	 	Konstantin Poukalov	 		  	Attn: Konstantin Poukalov
			
	AGREED TO AND ACCEPTED BY:	 		  	
	Fund	 		  	Address: c/o Perceptive Advisors, LLC
		 		 		  	51 Astor Place, 10th Floor, New York
	Perceptive Life Sciences Master Fund, Ltd.	 		  	NY 10003
				
	By:	 	 /s/ Joseph Edelman
	 		  	
	Name:	 	Joseph Edelman	 		  	Attn: James Mannix
	Title:	 	Authorized Representative	 		  	
			
	Perceptive Xontogeny Venture Fund, LP	 		  	Address: c/o Perceptive Advisors, LLC
		 		 		  	51 Astor Place, 10th Floor, New York
		 		 		  	NY 10003
				
	By:	 	 /s/ Joseph Edelman
	 		  	Attn: Sam Cohn
	Name:	 	Joseph Edelman	 		  	
	Title:	 	Authorized Representative	 		  	
			
	LEV LB Holdings, LP	 		  	Address: c/o Perceptive Advisors, LLC
		 		 		  	51 Astor Place, 10th Floor, New York
		 		 		  	NY 10003
				
	By:	 	 /s/ Joseph Edelman
	 		  	Attn: Sam Cohn
	Name:	 	Joseph Edelman	 		  	
	Title:	 	Manager	 		  	

 [Signature Page to Indemnification Agreement]EX-10.1

 Exhibit 10.1 

ARTERIS, INC. 
 INVESTOR
RIGHTS AGREEMENT 
 THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of February, 2016, by and among Arteris, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred
to in this Agreement as an “Investor”, and each of the holders of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”) listed on Schedule B, each of which is referred
to in this Agreement as a “Major Common Holder”. The Investors and the Major Common Holders shall be referred to herein collectively as the “Stockholders”. 

RECITALS 

WHEREAS, the Company has authorized the sale and issuance of shares of its Series A Preferred Stock, par value $0.001 per share (the
“Series A Preferred Stock”) pursuant to a Series A Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”); and 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company
pursuant to the Purchase Agreement, the Investors, the Major Common Holders and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors
and to receive certain information from the Company, and the right of the Stockholders to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement. 

AGREEMENT 

NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled
by one or more general partners or managing members of, or shares the same management company with, such Person. 
 1.2
“Board” means the Board of Directors of the Company. 
 1.3 “Common Stock” means shares of
the Company’s Common Stock, par value $0.001 per share. 

 1.4 “Damages” means any loss, damage, claim or liability
(joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based
upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party
(or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.7 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of
the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information
as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered. 
 1.8 “Form S-1” means such form
under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9 “Form S-3” means such form under the Securities Act as in effect
on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.10 “GAAP” means generally accepted accounting principles in the United States. 

1.11 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.12 “Immediate Family Member” means, for a natural person referred to herein, a child or other direct lineal
descendant, stepchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, niece or nephew, including adoptive relationships, or the spouse of any of the foregoing. 

  
 2 

 1.13 “Initiating Holders” means, collectively, Holders who
properly initiate a registration request under this Agreement. 
 1.14 “IPO” means the Company’s first
underwritten public offering of its Common Stock under the Securities Act. 
 1.15 “Key Executive Officer”
means the Company’s Chief Executive Officer, Chief Financial Officer, Chief Technology Officer, Vice Presidents and General Counsel. 

1.16 “Major Investor” means any Investor holding at least 200,000 shares of Series A Preferred Stock. 

1.17 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.18 “Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 1.19 “Preferred Director” means the director of the Company that the holders of record of
Series A Preferred Stock are entitled to elect pursuant to the Restated Certificate. 
 1.20 “Restated
Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as amended from time to time. 

1.21 “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Series
A Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof and (iii) any
Common stock issued as (or issuable upon the conversion or exercise of any warrant, right , or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clauses (i) and (ii) above, excluding however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding
for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 

1.22 “Registrable Securities then outstanding” means the number of shares determined by adding the number of
shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 

1.23 “Restricted Securities” means the securities of the Company required to be notated with the legend set
forth in Section 2.12(b) hereof. 

  
 3 

 1.24 “Requisite Major Common Holders” shall mean the Major
Common Holders holding a majority of the Stockholder Shares then held by all Major Common Holders who are then providing services to the Company as officers, employees, consultants or directors, it being understood and agreed that Arteris IP, LLC
shall be deemed to be providing services to the Company as an officer, employee, consultant or director so long as it or K. Charles Janac is providing services to the Company as an officer, employee, consultant or director. 

1.25 “SAS Acquisition” shall mean the acquisition (through a newly created subsidiary of the Company or
otherwise) by the Company of the operating assets and liabilities of Arteris, SAS, a French société par actions simplifiée. 

1.26 “Stockholder Shares” means Series A Preferred Stock, Common Stock, or Common Stock issued or issuable on
conversion of such Series A Preferred Stock held by any Investor or Major Common Holder. For purposes of votes or consents, these are accounted for on an as-if-converted
to Common Stock basis. 
 1.27 “Subsidiary” shall mean any entity in which the Company beneficially owns a
majority of the outstanding voting power. 
 1.28 “SEC” means the Securities and Exchange Commission. 

1.29 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.30 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.31 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.32 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Section 2.6. 
 1.33 “Series A Preferred Stock” means shares of the Company’s
Series A Preferred Stock, par value $0.001 per share. 
 1.34 “Ventech” means Ventech Capital F. 

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 
 (a)
Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration
statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least
a majority of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $15 million), then the Company shall (x) within thirty (30) days after the
date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is
given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional
Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject
to the limitations of Sections 2.1(c) and 2.3. 
 (b) Form S-3 Demand. If at
any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) the Registrable Securities then outstanding that the Company
file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million,
then the Company shall (i) within thirty (30) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five
(45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in
such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and
2.3. 
 (c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to
this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its
stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
twice in any twelve (12) month period. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares 

  
 5 

 
of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b).
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith
estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts
to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such
request. A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating
Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn
registration statement shall be counted as “effected” for purposes of this Section 2.1(d). 
 2.2
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the
public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days
after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such
registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to
include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by
their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s)
will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other
provision of this Section 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so
advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities,
including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided,
however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

  
 6 

 (b) In connection with any offering involving an underwriting of shares of the
Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting
as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities,
including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the
success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not
jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering
shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders.
Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the
offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling
Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering For purposes of the provision in this Section 2.3(b)
concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate
Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to
such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence. 

(c) For purposes of Section 2.1, a registration shall not be counted as “effected” if, as a result of an
exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than thirty percent (30%) of the total number of Registrable Securities that Holders have requested to be included in such registration
statement are actually included. 

  
 7 

 2.4 Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (h) promptly make available
for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders,
all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such
seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

  
 8 

 (i) notify each selling Holder, promptly after the Company receives notice thereof, of the
time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and
disbursements, not to exceed $35,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in
which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit
their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information] then the Holders shall not be required to pay
any of such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2
shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 
 2.7
Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 2. 

  
 9 

 2.8 Indemnification. If any Registrable Securities are included in a registration
statement under this Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold
harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each
Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person
any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably
withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder,
underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the
extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the
Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of
any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on
behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not
apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the
aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an indemnified party under this
Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the
indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an

  
 10 

 
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and
expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such action. 
 (d) To provide for just and equitable contribution to joint liability under the
Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of
a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material
fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct
or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by
such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder
pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall
survive the termination of this Agreement. 

  
 11 

 2.9 Reports Under Exchange Act. With a view to making available to the Holders the
benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company shall: 
 (a) make and keep available adequate current public information, as those
terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form
S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on
Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any
holder or prospective holder of any securities of the Company that allow such holder or prospective holder (i) to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may
include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder
to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with
Section 6.9. 
 2.11 “Market Stand-off” Agreement. Each
Stockholder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or
any other equity securities under the Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred
eighty (180) days or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and
opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), 

  
 12 

 (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase;
purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering, or 

(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. 

The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares
to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Stockholder or the Stockholder’s Immediate Family Member, provided that the trustee of the
trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value. The underwriters in connection with such registration are intended
third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Stockholder further agrees to execute such agreements as
may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. 

2.12 Restrictions on Transfer. 

(a) Stockholder Shares shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue
stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities
Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of Stockholder Shares to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. 

(b) Each certificate, instrument, or book entry representing the Stockholder Shares and any other securities issued in respect of the
Stockholder Shares or upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated with a legend
substantially in the following form: 
 THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

  
 13 

 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to
the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of
this Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Stockholder
thereof shall give notice to the Company of such Stockholder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and,
if reasonably requested by the Company, shall be accompanied at such Stockholder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to
the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such
Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that
the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted
Securities in accordance with the terms of the notice given by the Stockholder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or
(y) in any transaction in which such Stockholder distributes Restricted Securities to an Affiliate of such Stockholder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this
Section 2.12 Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate
restrictive legend set forth in Section 2.12(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Stockholder and the Company,
such legend is not required in order to establish compliance with any provisions of the Securities Act. 
 (d) Notwithstanding the
provisions of Section 2.12(a) to 2.12(c) above, no such restrictions on transfer shall apply to a transfer by a Stockholder that is (A) a partnership transferring to its partners or former partners in accordance
with partnership interests, (B) a venture fund transferring to its affiliated funds or any of their respective directors, officers or partners, (C) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns
all of the capital stock of the Stockholder, (D) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, or (E) an individual transferring to the
Stockholder’s Immediate Family Member or any trust for the benefit of an individual Stockholder or such Stockholder’s Immediate Family Member; provided that in each case and prior to any such transfer the transferee will agree in writing
to be subject to the terms of this Agreement to the same extent as if he were an original holder hereunder. 

  
 14 

 2.13 Termination of Registration Rights. The right of any Holder to request
registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Restated Certificate; 

(b) the five year anniversary of the IPO. 

3. Information Rights and Revenue Shortfall Warrants. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor: 

(a) as soon as practicable, but in any event within nine (9) months after the end of each fiscal year of the Company, (i) a balance
sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all prepared in accordance with GAAP and audited and certified by
independent public accountants of regionally recognized standing selected by the Board; and 
 (b) as soon as practicable, but in any event
at least twenty (20) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board and prepared on a monthly basis and, promptly after prepared,
any other budgets or revised budgets prepared by the Company. 
 If, for any period, the Company has any subsidiary whose accounts are
consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated
subsidiaries. 
 Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease
providing the information set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it
reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at
such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Termination of Information Rights. The covenants set forth in Section 3.1 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed
Liquidation Event (as defined in the Restated Certificate), whichever event occurs first. 

  
 15 

 3.3 Confidentiality. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s
intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.3 by such Investor), (b) is
or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach by such third party of
any obligation of confidentiality; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services
in connection with monitoring its investment in the Company, (ii) to any prospective purchaser of any Stockholder Shares from such Investor, if such prospective purchaser agrees to be bound by the provisions of this
Section 3, (iii) to any existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person
that such information is confidential and directs such Person to maintain the confidentiality of such information, or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure
and takes reasonable steps to minimize the extent of any such required disclosure. 
 3.4 Inspection. The Company shall permit each
Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such
reasonable times as may be requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Section 3.4 to provide access to any information which it reasonably considers to be a
trade secret or similar confidential information. 
 3.5 Revenue Shortfall Warrants. 

(a) If the Company’s 2016 Revenue (as defined below) is less than $16,500,000, then the Company shall issue to each Investor a warrant,
in the form attached hereto as Exhibit A, exercisable for that number of shares of Series A Preferred Stock equal to the product of (i) such Investor’s Series A Pro Rata Percentage (as defined below) and (ii) the Total Series A
Warrant Number (as defined below), rounded down to the nearest whole share (collectively, the “Series A Warrants”). 
 (b)
The Series A Warrants shall be issued to Investors no later than two weeks following completion of the 2016 Financials (as defined below). The Series A Warrants shall have an exercise price of $0.001 per share of Series A Preferred Stock. The
Company shall authorize and duly reserve 525,000 shares of Series A Preferred Stock and 525,000 shares of Common Stock for the potential issuance and exercise of the Series A Warrants. The Series A Warrants shall expire one year after issuance. 

(c) Additional Definitions: 

  
 16 

 (i) “2016 Revenue” shall mean the Company’s aggregate consolidated
GAAP revenue for fiscal year 2016 as set forth in the Company’s final annual audited financial statements for fiscal year 2016 (the “2016 Financials”); provided, however, that if the SAS Acquisition is consummated within 90
days of the date hereof, then “2016 Revenue” shall mean the aggregate consolidated GAAP revenue that the Company would have had in fiscal year 2016 if the SAS Acquisition had occurred on January 1, 2016. 

(ii) “Series A Pro Rata Percentage” with respect to each Investor shall mean the percentage obtained by dividing
(A) the number of shares of Series A Preferred Stock held by such Investor by (B) the aggregate number of shares of Series A Preferred Stock then outstanding. 

(iii) “Total Revenue Shortfall” shall mean the amount by which the Company’s aggregate consolidated GAAP revenue for
fiscal year 2016 falls below $16,500,000. 
 (iv) “Total Series A Warrant Number” shall mean the aggregate number of
shares of Series A Preferred Stock for which the Series A Warrants shall be exercisable for (the “Warrant Shares”) which shall equal the product of (A) 0.35 and (B) the Total Revenue Shortfall up to a maximum of 525,000 Warrant
Shares, provided that, the minimum Total Series A Warrant Number must equal at least 50,000 or no Series A Warrants shall be issued. 
 (d)
The covenants set forth in this Section 3.5 shall immediately terminate, and be of no further force or effect, and the Company shall have no obligation to issue the Series A Warrants, if the Company consummates a Deemed
Liquidation Event (as defined in the Restated Certificate) at anytime prior to December 31, 2016. 
 4. Rights to Future Stock
Issuances. 
 4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1
and applicable securities laws, if the Company proposes to offer or sell any New Securities, then the Company shall first offer such New Securities to each Stockholder. 

(a) The Company shall give notice (the “Offer Notice”) to each Stockholder, stating (i) its bona fide intention to
offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within ten (10) days after the Offer Notice is given, each Stockholder may elect to purchase or
otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Stockholder (including all shares of Common Stock then
issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Series A Preferred Stock and any other Derivative Securities then held by such Stockholder) bears to the total Common Stock of the Company then outstanding
(assuming full conversion and/or exercise, as applicable, of all Series A Preferred Stock but excluding (i) the exercise of any outstanding Derivative Securities, and (ii) any shares reserved for issuance under the Company’s equity
incentive plan). 

  
 17 

 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased
or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Stockholders in accordance with this Section 4.1. 
 (d) The right of first offer in this
Section 4.1 shall not be applicable to: 
 (i) shares of Common Stock and/or options, warrants or other Common
Stock purchase rights and the Common Stock issued pursuant to such options, warrants or other rights issued or to be issued after the date hereof to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary,
pursuant to the Company’s 2013 Equity Incentive Plan or any other stock purchase or stock option plans or other arrangements that are approved by an 80% majority of the Board (calculated as if all directors were present for the vote); 

(ii) stock issued or issuable pursuant to any rights or agreements, options, warrants or convertible securities outstanding as of the date of
this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first offer established by this Section 4 were complied with, waived, or were
inapplicable pursuant to any provision of this Section 4(d) with respect to the initial sale or grant by the Company of such rights or agreements; 

(iii) any New Securities issued for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business
combination approved by an 80% majority of the Board (calculated as if all directors were present for the vote); 
 (iv) any New Securities
issued in connection with any stock split, stock dividend or recapitalization by the Company; 
 (v) any New Securities issued pursuant to
any equipment loan or leasing arrangement, real property leasing arrangement, or debt financing from a bank or similar financial or lending institution approved by an 80% majority of the Board (calculated as if all directors were present for the
vote); 
 (vi) any New Securities that are issued by the Company pursuant to a registration statement filed under the Securities Act; 

(vii) any shares of Series A Preferred Stock issued pursuant to the Purchase Agreement; and 

(viii) any Series A Warrants issued by the Company pursuant to Section 3.5 of this Agreement. 

  
 18 

 (e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the
provisions of this Section 4.1, the Company may elect to give notice to the Stockholders within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New
Securities. Each Stockholder shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Stockholder, maintain such Stockholder’s percentage-ownership
position, calculated as set forth in Section 4.1(b) before giving effect to the issuance of such New Securities. 

4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect
(i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event (as defined in the Restated Certificate), whichever event occurs first. 

5. Additional Covenants. 

5.1 Insurance. The Company shall obtain, within forty-five (45) days of the date hereof, from financially sound and reputable
insurers Directors and Officers liability insurance in an amount and on terms and conditions satisfactory to the Board, and will cause such insurance policy to be maintained until such time as the Board determines that such insurance should be
discontinue. 
 5.2 Employee Agreements. The Company will cause each person now or hereafter employed by it or by any subsidiary (or
engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement. 

5.3 Employee Stock. Unless otherwise approved by the Board, all future employees and consultants of the Company who purchase, receive
options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four
(4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Section 2.11. 

5.4 Company’s Right of First Refusal. The Company’s Bylaws shall contain a right of first refusal on all transfers of Common
Stock (other than shares of Common Stock issuable upon conversion of Series A Preferred Stock), subject to customary exceptions. The Company’s Bylaws shall also contain a provision providing that no shares of Common Stock (other than shares of
Common Stock issuable upon conversion of Series A Preferred Stock) may be transferred except as approved by the Board in its discretion, which shall include, without limitation, refusal to allow any transfer to the extent such transfer would
increase the number of stockholders of the Company or require it to register, or register any class of equity securities, with the SEC. 

  
 19 

 5.5 Matters Requiring Supermajority Board Approval. So long as the holders of Series
A Preferred Stock are entitled to elect a Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of an 80% majority of the Board (calculated as if all directors were present for the
vote): 
 (a) adopt, approve or amend any annual budget; 

(b) acquire, transfer, dispose of, or pledge, or permit any Subsidiary to acquire, transfer, dispose of, or pledge, any asset worth more than
$250,000 unless provided for in the annual budget; 
 (c) materially modify its principal business strategy, enter into any new lines of
business, exit the current line of business, or materially modify its business plan; 
 (d) make any expenditure or commitment for an
expenditure, guarantee or pledge in excess of $250,000 unless provided for in the annual budget; 
 (e) create or hold capital stock in any
subsidiary that is not wholly owned (either directly or through one or more other subsidiaries) by the Company, or sell, transfer, pledge or otherwise dispose of, or permit any Subsidiary to sell, transfer, pledge or otherwise dispose of, any
capital stock of any direct or indirect subsidiary of the Company or such Subsidiary, as applicable, unless provided for in the annual budget; 

(f) grant any option grants or stock awards under its equity incentive plan; 

(g) enter into or be a party to any transaction with any stockholder, director, officer, or employee of the Company or any
“associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by this Agreement and the Purchase Agreement; 

(h) effect any Asset Sale (as defined in the Restated Certificate) or any merger, consolidation or reorganization of the Company or any
Subsidiary with or into another corporation, other than any merger, consolidation or reorganization of a Subsidiary into the Company or the merger, consolidation or reorganization of Subsidiaries into or with one another; 

(i) permit any Subsidiary to issue, sell or dispose any shares of its capital stock unless such shares are issued to the Company or another
Subsidiary; 
 (j) enter into any material agreement pursuant to which the Company grants exclusive rights for a fixed term exceeding three
(3) years; 
 (k) hire, terminate, or change the duties or compensation of any Key Executive Officer; 

(l) issue or obligate itself to issue shares of capital stock of the Company or any securities convertible into capital stock of the Company;

  
 20 

 (m) create any new Subsidiary except as set forth in Section 5.6; 

(n) hire any investment bank pursuant to Section 6.1 of that certain Amended and Restated Voting, Right of First Refusal and Co-Sale Agreement, dated as of the date hereof, by and among the Company and the parties listed on the signature pages thereto, as amended from time to time (the “Amended and Restated Voting, ROFR and Co-Sale Agreement”); 
 (o) select independent public accountants to audit the Company’s
financial statements; 
 (p) amend the Restated Certificate to increase the authorized number of shares of Series A Preferred Stock or
Common Stock or to effect a stock split or recapitalization; 
 (q) amend, alter or repeal any provision of the Restated Certificate or
Bylaws of the Corporation in a manner that adversely affects the powers, preferences or rights of the Series A Preferred Stock; 
 (r)
purchase or redeem (or permit any Subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than (i) redemptions of or dividends or distributions on the Series
A Preferred Stock as expressly authorized in the Restated Certificate, (ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, and (iii) repurchases of stock from former
employees, officers, directors, consultants or other persons who performed services for the Company or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair
market value thereof; or 
 (s) make any material change in the nature of the Corporation’s business. 

5.6 Commerce Department Compliance. The Company may be required to file reports with the Bureau of Economic Analysis (the
“BEA”) of the US Commerce Department when a US affiliate of a foreign Investor if such foreign Investor, together with its affiliates, directly or indirectly controls ten percent (10%) or more of the voting securities of the
Company. Such foreign Investor that is a foreign individual or entity or a US subsidiary or affiliate of a foreign parent covenants to provide information necessary for the Company to comply with BEA filings required under the International
Investment and Trade in Services Act. 
 5.7 Termination of Covenants. The covenants set forth in this Section 5 shall
terminate and be of no further force or effect upon the earlier of (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the
Exchange Act or (ii) upon a Deemed Liquidation Event (as defined in the Restated Certificate), whichever event occurs first. 

  
 21 

 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Stockholder
to a transferee of Stockholder Shares that (i) is an Affiliate of a Stockholder; (ii) is a Stockholder’s Immediate Family Member or trust for the benefit of an individual Stockholder or one or more of such Stockholders’ Immediate
Family Members; or (iii) after such transfer, holds at least 10,000 Stockholder Shares (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Stockholder Shares with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement. For the purposes of determining the number of shares of Stockholder Shares held by a transferee, the
holdings of a transferee (1) that is an Affiliate or stockholder of a Stockholder; (2) who is a Stockholders’ Immediate Family Member; or (3) that is a trust for the benefit of an individual Stockholder or such Stockholders’
Immediate Family Member shall be aggregated together and with those of the transferring Stockholder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to
the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by the internal law of the State of Delaware. 

6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at their addresses as set forth on Schedule A 

  
 22 

 
or Schedule B hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile
number, or address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy shall also be sent to Company counsel at the address set forth below: 

Company counsel: 

Cooley LLP 

Attention: Laura Medina, Esq. 

380 Interlocken Crescent, Suite 900 

Broomfield, CO 80021 

Facsimile: (720) 566-4099 

6.6 Amendments and Waivers. Any term of this Agreement may be amended, modified or terminated and the observance of any term of this
Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of (i) the Company, (ii) the Investors holding a majority of the Registrable Securities then
outstanding and held by all Investors, and (iii) the Requisite Major Common Holders; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to
object promptly in writing after notification of a proposed assignment allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by
any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any
Investor or Major Common Holder without the written consent of such Investor or Major Common Holder unless such amendment, or termination or waiver applies to all Investors or Major Common Holders, as the case may be, in the same fashion (it being
agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Stockholders in the same fashion if such waiver does so by its terms, notwithstanding the fact
that certain Stockholders may nonetheless, by agreement with the Company, purchase securities in such transaction). Notwithstanding the foregoing, Schedule A and Schedule B hereto may be amended by the Company from time
to time to add information regarding additional Investors or Major Common Holders who become a party to this Agreement pursuant to Sections 6.1 or 6.9 without the consent of the other parties hereto. The Company shall give prompt
notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this
Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more
instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 
 6.7
Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other
provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

  
 23 

 6.8 Aggregation of Stock. All Stockholder Shares held or acquired by Affiliates
shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Series A Preferred Stock after the date hereof, any purchaser of such shares may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed
an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in writing to be bound by all
of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement. This Agreement (including any Schedules and
Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is
expressly canceled. 
 6.11 Dispute Resolution. 

(a) Any unresolved controversy or claim arising out of or relating to this Agreement, except as (i) otherwise provided in this
Agreement, or (ii) any such controversies or claims for which a provisional remedy or equitable relief is sought, shall be submitted to binding arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be
reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the “AAA”), then by one arbitrator having reasonable experience in corporate finance transactions
of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in the State of California in Santa Clara County, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such
arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and
documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in
accordance with the State of California Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such
record constituting the official transcript of such proceedings. Each party will bear its own costs in respect of any disputes arising under this Agreement. The language of the arbitration shall be English. The prevailing party shall be entitled to
reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Notwithstanding anything to the contrary herein, each party shall be entitled, at any time, to seek injunctive
or other equitable relief from any court of competent jurisdiction, wherever such party deems appropriate, in order to preserve or enforce such party’s rights hereunder. Each of the parties to this Agreement consents to personal jurisdiction
for any equitable action sought in the U.S. District Court for the Northern District of California or any court of the State of California having subject matter jurisdiction. 

  
 24 

 (b) By agreeing to this binding arbitration provision, the parties understand that they are
waiving certain rights and protections which may otherwise be available if a dispute between the parties were determined by litigation in court, including, without limitation, the right to seek or obtain certain types of damages precluded by this
arbitration provision, the right to a jury trial, certain rights of appeal, and a right to invoke formal rules of procedure and evidence. 

(c) Each party acknowledges that money damages would not be a sufficient remedy for any breach of this Agreement by such party, that it may
be difficult to ascertain the damages which would be suffered by the other parties in such cases, and that the other parties would suffer irreparable harm as a result of any such breach. Accordingly, each party will also be entitled to equitable
relief, including injunction and specific performance, as a remedy for any breach or threatened breach of this Agreement by the other party. The equitable remedies referred to above will not be deemed to be the exclusive remedies for a breach of
this Agreement, but rather will be in addition to all other remedies available to the parties. 
 6.12 Delays or Omissions. No delay
or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such
non-breaching or non-defaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default
occurring before or thereafter, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default occurring before or thereafter. All remedies, whether under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 

  
 25 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
written above. 
  

			
	
	COMPANY:
	
	ARTERIS, INC.
		
	Signature:	 	/s/ K. Charles Janac
	Name:	 	K. Charles Janac
	Title:	 	President and CEO
		
	Address:	 	
	
	 Arteris, Inc.
 Worldwide
Headquarters
 591 W Hamilton Ave
 Suite 250

Campbell, CA 95008
 USA

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	MAJOR COMMON HOLDER:
	
	ARTERIS IP, LLC
		
	Signature:	 	/s/ K. Charles Janac
	Name:	 	K. Charles Janac
	Title:	 	President and CEO

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	VENTECH CAPITAL F
		
	Signature:	 	/s/ C. Claussen
	Name:	 	C. Claussen
	Title:	 	General Partner

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	GREY CORP GMBH
		
	Signature:	 	/s/ Robert Wuttke
	Name:	 	Robert Wuttke
	Title:	 	Managing Director

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	ARTERIS IP, LLC
		
	Signature:	 	/s/ K. Charles Janac
	Name:	 	K. Charles Janac
	Title:	 	President and CEO

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	BARRY AND JODY TURKUS TRUST
		
	Signature:	 	/s/ Barry A. Turkus
	Name:	 	Barry A. Turkus
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	CRESCENDO VENTURES 401K PROFIT SHARING PLAN FBO WAYNE CANTWELL
		
	Signature:	 	/s/ Wayne Cantwell
	Name:	 	Wayne Cantwell
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	AMY F MILLER REVOCABLE TRUST
		
	Signature:	 	/s/ Amy F. Miller
	Name:	 	Amy F. Miller
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
			
	INVESTORS:
	
	JANAC TRUST
		
	Signature:	 	/s/ K. Charles Janac
	Name:	 	K. Charles Janac
	Title:	 	Trustee

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
	
	INVESTORS:
	
	/s/ Stéphane Mehat
	STÉPHANE MEHAT

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 
	
	INVESTORS:
	
	/s/ Kurtis Shuler
	KURTIS SHULER

  

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 SCHEDULE A 

Investors 
 VENTECH
CAPITAL F  
 ### 

GREY CORP GMBH  

### 
 BARRY AND
JODY TURKUS TRUST  
 ### 

JANAC TRUST  
 ### 

ARTERIS IP, LLC  
 ### 

CRESCENDO VENTURES 401K PROFIT SHARING PLAN FBO
WAYNE CANTWELL  
 ### 

STÉPHANE MEHAT  
 ###

 KURTIS SHULER  
 ###

 AMY F MILLER REVOCABLE TRUST  

### 

 SCHEDULE B 

Major Common Holders 

ARTERIS IP, LLC  
 Suite 250 

591 W. Hamilton Ave. 
 Campbell CA 95008 

United States 

 EXHIBIT A 

FORM OF SERIES A WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]